We are delighted to announce the release of a panel of murine monoclonal antibodies against the SARS-CoV-2 Spike protein.
SARS-CoV-2 is a positive-sense, single-stranded RNA virus which causes the acute respiratory disease COVID-19. The S protein is the main surface antigen of SARS-CoV-2.
The receptor-binding domain (RBD) in the S protein specifically binds to angiotensin-converting enzyme 2 (ACE2) on target cells, mediating SARS-CoV-2 host cell entry. Our antibodies bind a variety of epitopes on the Spike protein, within and outside of the RBD, and have varying abilities to neutralize SARS-CoV-2 and to block the ability of the Spike protein of the virus to bind the ACE2 receptor.